文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Smith D A, Chandler M H, Shedlofsky S I, Wedlund P J, Blouin R A

College of Pharmacy, University of Kentucky, Lexington 40536-0082.

Br J Clin Pharmacol. 1991 Dec;32(6):735-9.

The disposition of hexobarbitone enantiomers before and after rifampicin treatment (600 mg daily for 14 days) was investigated in six young (29 +/- 3 years old) and six elderly (71 +/- 4 years old) healthy male volunteers. Hexobarbitone was given as a single 500 mg oral dose of the racemate. 2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects. 3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.

在6名年轻（29±3岁）和6名老年（71±4岁）健康男性志愿者中，研究了利福平治疗前后（每日600mg，共14天）异戊巴比妥对映体的处置情况。异戊巴比妥以500mg外消旋体单次口服给药。2. 在年轻和老年受试者中，S-(+)异戊巴比妥的平均（±标准差）口服清除率分别为1.9±0.3和1.8±0.2ml·min⁻¹·kg⁻¹，在年轻和老年受试者中，利福平治疗14天后均增加约6倍（年轻受试者增至11.9±2.2ml·min⁻¹·kg⁻¹，老年受试者增至10.7±2.8ml·min⁻¹·kg⁻¹）。3. 相比之下，利福平治疗使年轻和老年受试者中R-(-)异戊巴比妥的口服清除率有更大且不同的增加；年轻受试者增加了89倍（从15.6±16.4增至1146.7±1478.0ml·min⁻¹·kg⁻¹），老年受试者增加了19倍（从10.3±3.0增至199.9±98.1ml·min⁻¹·kg⁻¹）。

Smith D A, Chandler M H, Shedlofsky S I, Wedlund P J, Blouin R A

College of Pharmacy, University of Kentucky, Lexington 40536-0082.

Br J Clin Pharmacol. 1991 Dec;32(6):735-9.

The disposition of hexobarbitone enantiomers before and after rifampicin treatment (600 mg daily for 14 days) was investigated in six young (29 +/- 3 years old) and six elderly (71 +/- 4 years old) healthy male volunteers. Hexobarbitone was given as a single 500 mg oral dose of the racemate. 2. The mean (+/- s.d.) oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects. 3. In contrast, rifampicin treatment produced a larger and a differential increase in the oral clearance of R-(-) hexobarbitone in young and elderly subjects; an 89 fold change in the young (15.6 +/- 16.4 to 1146.7 +/- 1478.0 ml min-1 kg-1) and a 19 fold change (10.3 +/- 3.0 to 199.9 +/- 98.1 ml min-1 kg-1) in the elderly.

在6名年轻（29±3岁）和6名老年（71±4岁）健康男性志愿者中，研究了利福平治疗前后（每日600mg，共14天）异戊巴比妥对映体的处置情况。异戊巴比妥以500mg外消旋体单次口服给药。2. 在年轻和老年受试者中，S-(+)异戊巴比妥的平均（±标准差）口服清除率分别为1.9±0.3和1.8±0.2ml·min⁻¹·kg⁻¹，在年轻和老年受试者中，利福平治疗14天后均增加约6倍（年轻受试者增至11.9±2.2ml·min⁻¹·kg⁻¹，老年受试者增至10.7±2.8ml·min⁻¹·kg⁻¹）。3. 相比之下，利福平治疗使年轻和老年受试者中R-(-)异戊巴比妥的口服清除率有更大且不同的增加；年轻受试者增加了89倍（从15.6±16.4增至1146.7±1478.0ml·min⁻¹·kg⁻¹），老年受试者增加了19倍（从10.3±3.0增至199.9±98.1ml·min⁻¹·kg⁻¹）。